The calcium-release-activated calcium (CRAC) channel, activated by the discharge of Ca2+Â from the endoplasmic reticulum (ER), is important for Ca2+Â homeostasis and energetic sign transduction in a plethora of cell sorts. Spurred by the long-sought decryption of the molecular nature of the CRAC channel, appreciable scientific effort has been dedicated to gaining insights into purposeful and structural mechanisms underlying this signalling cascade. Key gamers in CRAC channel operate are the Stromal interplay molecule 1 (STIM1) and Orai1. STIM1 proteins span via the membrane of the ER, are competent in sensing luminal Ca2+Â focus, and in flip, are answerable for relaying the sign of Ca2+Â store-depletion to pore-forming Orai1 proteins within the plasma membrane.
A direct interplay of STIM1 and Orai1 permits for the re-entry of Ca2+Â from the extracellular area. Although a lot is already recognized concerning the construction, operate, and interplay of STIM1 and Orai1, there may be rising proof that CRAC below physiological circumstances depends on further proteins to operate correctly. Several auxiliary proteins have been proven to manage CRAC channel exercise by means of direct interactions with STIM1 and/or Orai1, selling or hindering Ca2+Â inflow in a mechanistically numerous method. Various proteins have additionally been recognized to exert a modulatory function on the CRAC signalling cascade though inherently missing an affinity for each STIM1 and Orai1.
Apart from ubiquitously expressed representatives, a subset of such regulatory mechanisms appears to permit for a cell-type-specific management of CRAC channel operate, contemplating the fairly restricted expression patterns of the particular proteins. Given the excessive purposeful and scientific relevance of each generic and cell-type-specific interacting networks, the next overview shall present a complete abstract of regulators of the multilayered CRAC channel signalling cascade. It additionally consists of proteins expressed in a slim spectrum of cells and tissues which can be typically disregarded in different evaluations of comparable matters.
An IOHMM-Based Framework to Investigate Drift in Effectiveness of IoT-Based Systems
IoT-based methods, when interacting with the bodily atmosphere via actuators, are complicated methods troublesome to mannequin. Formal verification strategies carried out at design-time being typically ineffective on this context, these methods should be quantitatively evaluated for effectiveness at run-time, i.e., for the extent to which they behave as anticipated. This analysis is achieved by confronting a mannequin of the results they need to legitimately produce in numerous contexts to these noticed within the discipline. However, this quantitative analysis is just not informative on the drifts in effectiveness, it doesn’t assist designers examine their attainable causes, growing the time wanted to resolve them.
To deal with this drawback, and assuming that fashions of official conduct could be described by means of Input-Output Hidden Markov Models (IOHMMs), a novel generic unsupervised clustering-based IOHMM construction and parameters studying algorithm is developed. This algorithm is first used to study a mannequin of official conduct. Then, a mannequin of the noticed conduct is realized from observations gathered within the discipline. A second algorithm builds a dissimilarity graph that makes clear structural and parametric variations between each fashions, thus offering steering to designers to assist them examine attainable causes of drift in effectiveness. The method is validated on a actual world dataset collected in a sensible residence.
Chaos conduct has been noticed in varied mobile and molecular processes. Here, we modeled reversible phosphorylation dynamics to elucidate a design precept for autonomous chaos era that will come up from generic enzymatic reactions. A complete parameter search demonstrated that the response system composed of a set of kinases and phosphatases and two substrates with two modification websites reveals chaos conduct. All reactions are described in accordance with the Michaelis-Menten response scheme with out unique capabilities being utilized to enzymes and substrates. Clustering evaluation of parameter units that may generate chaos conduct revealed the existence of motif constructions.
These chaos motifs enable the two-substrate species to work together through enzyme availability and constrain the 2 substrates’ dynamic modifications in phosphorylation standing in order that they happen at completely different timescales. This chaos motif construction is present in a number of enzymatic reactions, suggesting that chaos conduct could underlie mobile autonomy in a selection of biochemical methods.
Leveraging Image Analysis to Compute 3D Plant Phenotypes Based on Voxel-Grid Plant Reconstruction
High throughput image-based plant phenotyping facilitates the extraction of morphological and biophysical traits of a giant quantity of vegetation non-invasively in a comparatively brief time. It facilitates the computation of superior phenotypes by contemplating the plant as a single object (holistic phenotypes) or its parts, i.e., leaves and the stem (element phenotypes). The architectural complexity of vegetation will increase over time resulting from variations in self-occlusions and phyllotaxy, i.e., preparations of leaves across the stem.
Lambda Light Chain Antibody / Lambda Antibody |
V7879-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
R20161-100UG |
NSJ Bioreagents |
100ug |
EUR 347.65 |
Description: This recombinant Mouse Lambda Light Chain antibody reacts to the lambda light chain of murine immunoglobulins. No cross reactivity with the kappa chain or human/rat/goat IgG. |
Lambda Light Chain Antibody / Lambda Antibody |
R20161BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 347.65 |
Description: This recombinant Mouse Lambda Light Chain antibody reacts to the lamda light chain of mouse immunoglobulins. No cross reactivity with the kappa light chain, human IgG, rat IgG, or goat IgG. |
Lambda Light Chain Antibody / Lambda Antibody |
R20161SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 832.15 |
Description: This recombinant Mouse Lambda Light Chain antibody reacts to the lambda light chain of murine immunoglobulins. No cross reactivity with the kappa chain or human/rat/goat IgG. |
Lambda Light Chain Antibody / Lambda Antibody |
R20179-100UG |
NSJ Bioreagents |
100ug |
EUR 347.65 |
Description: This recombinant Human Lambda Light Chain antibody reacts to the lambda light chain of human immunoglobulins. No cross reactivity with the kappa light chain or mouse/rat/goat IgG. |
Lambda Light Chain Antibody / Lambda Antibody |
R20179BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 347.65 |
Description: This recombinant Human Lambda Light Chain antibody reacts to the lambda light chain of human immunoglobulins. No cross reactivity with the kappa light chain, mouse IgG, rat IgG, or goat IgG |
Lambda Light Chain Antibody / Lambda Antibody |
R20179SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 832.15 |
Description: This recombinant Human Lambda Light Chain antibody reacts to the lambda light chain of human immunoglobulins. No cross reactivity with the kappa light chain or mouse/rat/goat IgG. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 349.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 349.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
RQ4975 |
NSJ Bioreagents |
100ul |
EUR 356.15 |
Description: All five immunoglobulin classes share the same basic four polypeptide chain structure of two heavy-chains and two light chains. There are five heavy chain types, and two light-chain types (Kappa and Lambda) both having a molecular weight of 22.5kDa. Any heavy-chain type can associate with either light-chain type, but on any immunoglobulin molecule both light-chains are of the same type. |
Lambda Light chain Antibody |
43108-100ul |
SAB |
100ul |
EUR 302.4 |
lambda light chain Antibody |
abx034778-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
lambda light chain Antibody |
abx034778-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Lambda Light Chain Antibody |
V8873-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody |
V8873-20UG |
NSJ Bioreagents |
20ug |
EUR 153.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody |
V8873SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light chain Antibody |
43108 |
SAB |
100ul |
EUR 319 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx411151-1mg |
Abbexa |
1 mg |
EUR 661.2 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx411423-05mg |
Abbexa |
0.5 mg |
EUR 794.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx413204-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415391-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415790-1mg |
Abbexa |
1 mg |
EUR 526.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415793-05mg |
Abbexa |
0.5 mg |
EUR 477.6 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415798-1mg |
Abbexa |
1 mg |
EUR 661.2 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415800-05mg |
Abbexa |
0.5 mg |
EUR 477.6 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx414083-025mg |
Abbexa |
0.25 mg |
EUR 678 |
|
Ig lambda Light Chain Antibody |
20-abx137078 |
Abbexa |
|
|
|
Free lambda Light Chain Antibody |
abx023820-1mg |
Abbexa |
1 mg |
EUR 718.8 |
|
Rabbit Lambda light chain antibody |
70R-10680 |
Fitzgerald |
1 ml |
EUR 417.6 |
Description: Rabbit polyclonal Lambda light chain antibody |
Lambda Light Chain (Lambda-IgLC) Antibody (AP) |
abx411154-1ml |
Abbexa |
1 ml |
EUR 678 |
|
Lambda Light Chain Antibody Cocktail |
V2155-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This antibody cocktail is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Lambda light chain antibody is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody Cocktail |
V2155-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: This antibody cocktail is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Lambda light chain antibody is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody Cocktail |
V2155IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: This antibody cocktail is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Lambda light chain antibody is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody Cocktail |
V2155SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: This antibody cocktail is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Lambda light chain antibody is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx411155-1ml |
Abbexa |
1 ml |
EUR 594 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (RPE) |
abx411223-05mg |
Abbexa |
0.5 mg |
EUR 927.6 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (RPE) |
abx413206-100tests |
Abbexa |
100 tests |
EUR 710.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx415792-1ml |
Abbexa |
1 ml |
EUR 594 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx415795-1ml |
Abbexa |
1 ml |
EUR 594 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (RPE) |
abx415796-05ml |
Abbexa |
0.5 ml |
EUR 760.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx414084-025mg |
Abbexa |
0.25 mg |
EUR 710.4 |
|
Lambda Light Chain(Lamb14) Antibody |
BNC800860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF680 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC800860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF680 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC810860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF680R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC810860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF680R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC940860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF594 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC940860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF594 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC700860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF770 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC700860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF770 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC880860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF488A conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC880860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF488A conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC050860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF405M conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC050860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF405M conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC040860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF405S conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC040860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF405S conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC400860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF640R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC400860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF640R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCB0860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Biotin conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCB0860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Biotin conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCAP0860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCAP0860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCA0860-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Lambda Light Chain(Lamb14), APC conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCR0860-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Lambda Light Chain(Lamb14), RPE conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCP0860-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Lambda Light Chain(Lamb14), PerCP conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNUM0860-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against Lambda Light Chain(Lamb14), 1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCH0860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNCH0860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNUB0860-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Concentration: 0.2mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNUB0860-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against Lambda Light Chain(Lamb14), Concentration: 0.2mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC610860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF660R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC610860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF660R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC550860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF555 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC550860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF555 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC430860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF543 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC430860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF543 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC680860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF568 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC680860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF568 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC470860-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF647 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(Lamb14) Antibody |
BNC470860-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(Lamb14), CF647 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx411152-1mg |
Abbexa |
1 mg |
EUR 811.2 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx413205-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx415791-1mg |
Abbexa |
1 mg |
EUR 560.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx415794-05mg |
Abbexa |
0.5 mg |
EUR 526.8 |
|
Lambda Light Chain(LAM03) Antibody |
BNCA0636-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Lambda Light Chain(LAM03), APC conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC800636-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF680 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC800636-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF680 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC810636-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF680R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC810636-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF680R conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC940636-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF594 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC940636-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF594 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC700636-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF770 conjugate, Concentration: 0.1mg/mL |
Lambda Light Chain(LAM03) Antibody |
BNC700636-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Lambda Light Chain(LAM03), CF770 conjugate, Concentration: 0.1mg/mL |
One of the central challenges to computing phenotypes from 2-dimensional (2D) single view photographs of vegetation, particularly on the superior vegetative stage in presence of self-occluding leaves, is that the knowledge captured in 2D photographs is incomplete, and therefore, the computed phenotypes are inaccurate. We introduce a novel algorithm to compute three-dimensional (3D) plant phenotypes from multiview photographs utilizing voxel-grid reconstruction of the plant (3DPhenoMV). The paper additionally presents a novel technique to reliably detect and separate the person leaves and the stem from the 3D voxel-grid of the plant utilizing voxel overlapping consistency verify and level cloud clustering strategies. To consider the efficiency of the proposed algorithm, we introduce the University of Nebraska-Lincoln 3D Plant Phenotyping Dataset (UNL-3DPPD).